Latest Kaiser Health News Stories
Readers and Tweeters Shed Light on Vaccine Trials and Bias in Health Care
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Scientists Warn Americans Are Expecting Too Much From a Vaccine
Some argue that vaccines capable of preventing any COVID-19 symptoms should qualify for widespread use, but others want much larger trials to prove the vaccines can reduce hospitalizations or deaths.
Florida Fails to Attract Bidders for Canada Drug Importation Program
No private firms bid on the $30 million contract to set up and operate the state’s plan to bring in cheaper drugs. The setback is likely to delay by at least several months Florida’s effort to become the first state to import drugs under new federal regulations.
Progressive Group Highlights Trump, Tillis Weakness on Insulin Price Tags
The progressive Change Now PAC launched a campaign ad, which also circulated on Facebook, criticizing President Donald Trump and Sen. Thom Tillis (R-N.C.) for not “fighting” for people with diabetes who struggle with the high cost of insulin.
COVID-19: las farmacéuticas elogiadas por Trump mandan dinero a Biden
Revirtiendo una tendencia en las contribuciones de las farmacéuticas, que enviaban mucho dinero a los republicanos, en lo que va de 2020 la industria se ha inclinado hacia los demócratas.
As Trump Touts His ‘Great’ COVID Drugs, the Pharma Cash Flows to Biden, Not Him
President Donald Trump has been heralding drugmakers as “great companies.” Yet in the final stretch of the presidential campaign, Trump is not feeling the love in pharma contributions. Former Vice President Joe Biden is, even though his proposed policies could dent the industry’s profitability.
5 cosas que debes saber sobre la vacuna para COVID. Primero: no será una “bala mágica”
Hay docenas de vacunas candidatas que se están probando, y 11 de ellas están en la etapa final de investigación, cuatro en los Estados Unidos.
5 Things to Know About a COVID Vaccine: It Won’t Be a ‘Magic Wand’
Approval of a vaccine will be an important step in defeating COVID-19. But it won’t immediately end the pandemic.
Old Drug Turned ‘Cash Cow’ as Company Pumped Price to $40K a Vial, Emails Show
The CEO of Mallinckrodt Pharmaceuticals defended the price hikes of Acthar gel, an orphan drug that treats infantile spasms at a House Oversight Committee hearing on Thursday.
KHN’s ‘What the Health?’: Election Preview: What’s Next for Health?
How will health issues affect voter choices? What will happen if President Donald Trump is reelected or the White House goes to Joe Biden? In this special election preview episode, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
New Laws Keep Pandemic-Weary California at Forefront of Health Policy Innovation
Gov. Gavin Newsom approved many consequential health care bills by his bill-signing deadline Wednesday, including a ban on the sale of menthol and other flavored tobacco products, the creation of a state generic drug label and better coverage for mental health disorders.
Sky-High Drug Prices Driven by Pharma Profits, House Dems Charge
Democrats on the House Oversight Committee released a damning investigation Wednesday of drug company pricing tactics and profits, as two days of hearings with testimony from pharmaceutical industry CEOs begin.
Promises Kept? On Health Care, Trump’s Claims of ‘Monumental Steps’ Don’t Add Up
The president entered office seeking to overturn the Affordable Care Act, revamp Medicaid and drive down prescription drug prices, among other things. He’s hit some stone walls.
Trump Approves Final Plan to Import Drugs From Canada ‘for a Fraction of the Price’
The announcement clears the way for Florida and other states to implement a program bringing medications across the border to save money. The effort is strongly opposed by drugmakers and the Canadian government.
KHN’s ‘What the Health?’: ACA in Peril With Ginsburg’s Seat in Play
The death of Supreme Court Justice Ruth Bader Ginsburg is giving new life to the latest constitutional challenge to the Affordable Care Act. It also places anti-abortion activists on the cusp of a court majority large enough to ensure the rollback of the right to abortion and, possibly, some types of birth control. Meanwhile, Health and Human Services Secretary Alex Azar tries to centralize power at the sprawling department plagued by miscommunications and scandals. Anna Edney of Bloomberg News, Kimberly Leonard of Business Insider and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Sarah Jane Tribble about her new podcast, “Where It Hurts,” debuting Sept. 29.
These Secret Safety Panels Will Pick the COVID Vaccine Winners
Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.
It’s Not Just Insulin: Lawmakers Focus on Price of One Drug, While Others Rise Too
While insulin is the poster child for outrageous prescription costs, patients are paying ever more to treat depression, asthma, HIV, cholesterol and more. And the pandemic has overtaken efforts to force the issue in Congress.
Señales de una “vacuna sorpresa en octubre” alarma a científicos de carrera
El presidente Donald Trump, que parece decidido a anunciar una vacuna para COVID-19 antes de las elecciones, podría autorizarla legalmente a pesar de las objeciones.
Signs of an ‘October Vaccine Surprise’ Alarm Career Scientists
President Donald Trump has the legal power to authorize a COVID vaccine over the objections of the Food and Drug Administration and vaccine manufacturers. Such a move could further erode public trust in a vaccine and foist an unsafe shot on Americans.
¿Regalo para Florida? Trump aprobaría pronto importación de medicamentos de Canadá
A pesar de las objeciones de las farmacéuticas, se espera que la administración Trump finalice pronto el plan que permitiría a los estados importar medicamentos de venta bajo receta.
